US Patent

US10201541 — Compositions and methods for treating HCV

Formulation · Assigned to AbbVie Inc · Expires 2032-05-17 · 6y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions that combine two or more therapeutic agents for inhibiting the hepatitis C virus.

USPTO Abstract

This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.

Drugs covered by this patent

Patent Metadata

Patent number: US10201541
Jurisdiction: US
Classification: Formulation
Expires: 2032-05-17
Drug substance claim: No
Drug product claim: Yes
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.